STRM.BIO
Based in Cambridge, MA, STRM.BIO is developing extracellular vesicles to deliver gene therapies in vivo. Our platform is differentiated by: (1) a natural tropism and preferential targeting to long-term hematopoietic stem cells (earliest progenitor desired for durable correction), (2) tunable loading that supports protein and nucleic acid cargo delivery in vivo, and (3) ability to repeat dose. The company’s lead therapeutic programs are targeting rare blood diseases.
